# ONUREG (azacitidine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/azacitidine

> The FDA approved ONUREG (azacitidine), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on September 1, 2020.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ONUREG (azacitidine) |
| Codes | CC-486 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | [acute myeloid leukemia](https://sec-api.dev/indications/acute-myeloid-leukemia), [Leukemia, Myeloid, Acute](https://sec-api.dev/indications/leukemia-myeloid-acute) |
| Modality |  |
| FDA designations | accelerated, priority review |

## Timeline

### September 1, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214120 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20200901, review_priority PRIORITY; sponsor_name BRISTOL; product ONUREG (AZACITIDINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214120%22

### May 20, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA050794 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20220520, review_priority PRIORITY; sponsor_name BRISTOL-MYERS; product VIDAZA (AZACITIDINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA050794%22

### Oct 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2026-03-06, last confirmed 2026-03-06.
- SEC Form 10-K (accession 0001193125-26-095014): "In October 2024, we announced that we are collaborating with the MD Anderson Cancer Center and the Memorial Sloan Kettering Cancer Center to support an investigator-initiated Phase 1b study, which is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of rezatapopt monotherapy in combination with azacitidine in R/R AML and MDS patients harboring a TP53 Y220C mutation." https://www.sec.gov/Archives/edgar/data/1699382/000119312526095014/pmvp-20251231.htm

### November 20, 2024: trial start

- Status: completed. Date confidence: exact. Indication: Acute Myeloid Leukemia.
- First seen 2024-11-20, last confirmed 2024-11-20.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-129018): "Seattle, Washington, November 20, 2024 - Aptevo Therapeutics ("Aptevo") (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today expanded on the potential of mipletamig, currently being evaluated as frontline therapy for the treatment of Acute Myeloid Leukemia (AML), in combination with standard of care venetoclax and azacitidine, noting the first patient dosed in the ongoing RAINIER trial achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies." https://www.sec.gov/Archives/edgar/data/1671584/000095017024129018/apvo-ex99_1.htm

### October 31, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Leukemia, Myeloid, Acute.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05413018 (An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-31 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05413018

### April 9, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214120 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20260409, review_priority STANDARD; sponsor_name BRISTOL; product ONUREG (AZACITIDINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214120%22

### 1H 2027: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-10-26, last confirmed 2026-10-26.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-431079): "Aptevo expects the RAINIER dose optimization trial to conclude by year-end, with FDA interaction and initiation of a Phase 2 clinical trial anticipated in the first half of 2027" https://www.sec.gov/Archives/edgar/data/1671584/000119312526431079/apvo-ex99_1.htm

## Same indication

- [Annamycin](https://sec-api.dev/pdufa/annamycin) (MBRX)
- [Bleximenib](https://sec-api.dev/pdufa/bleximenib) (JNJ)
- [Tambiciclib](https://sec-api.dev/pdufa/tambiciclib) (SLS)
- [TSC-101](https://sec-api.dev/pdufa/tsc-101) (TCRX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/azacitidine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ONUREG (azacitidine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/azacitidine

```bibtex
@misc{secapidev_pdufa_azacitidine_20261116,
  title        = {ONUREG (azacitidine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/azacitidine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_azacitidine_20261116","title":"ONUREG (azacitidine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/azacitidine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
